Clinical Trial

A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Performance at Varying Dosages in Healthy Middle-aged and Older Adults With Self-reported Memory Problems

Recruiting

Summary

The goal of this clinical trial is to investigate the safety and efficacy of AP-Brain on cognitive performance at varying dosages in healthy middle-aged and older adults with self-reported memory problems. The main question it aims to answer is: What is the effect of AP-Brain at 1 g, 3 g, and 5 g on cognitive performance? Participants will be asked to consume AP-Brain at 1 g, 3 g, or 5g, or Placebo and asked to complete memory assessment questionnaires.

Protocol Amendment History 6 changes

critical Recruitment opened 2026-06-25

critical Primary endpoint(s) modified 2026-06-25

notable Primary completion pushed: 2026-10 -> 2026-11 2026-06-25

minor Completion pushed: 2026-10 -> 2026-11 2026-06-25

notable Primary completion pushed: 2026-05 -> 2026-10 2026-04-25

minor Completion pushed: 2026-05 -> 2026-10 2026-04-25

Trial Details

NCT Number	NCT07388043
Lead Sponsor	Rousselot BVBA Collaborators: KGK Science Inc.
Conditions	Cognition, Cognitive Performance
Enrollment	120 participants
Start Date	2026-06
Primary Completion	2026-11 (estimated)
Study Completion	2026-11 (estimated)
Updated on ClinicalTrials.gov	2026-06-24